Palbociclib
Product Description
| Catalogue Number | P139900 |
| Chemical Name | Palbociclib |
| Synonyms | 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; PD 0332991; PD 332991; |
| CAS Number | 571190-30-2 |
| Alternate CAS # | 827022-32-2 HCl salt |
| Molecular Formula | C₂₄H₂₉N₇O₂ |
| Appearance | Pale Yellow to Green Solid |
| Melting Point | >244°C (dec.) |
| Molecular Weight | 447.53 |
| Storage | 4°C |
| Solubility | Chloroform (Slightly), DMSO (Slightly, Heated), Methanol (Slightly, Heated) |
| Category | Research Tools; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
| Applications | Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. |
| References | Finn, R., et al.: Breast Cancer Res., 11, 5 (2009); |
